Profile data is unavailable for this security.
About the company
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC., is a biopharmaceutical company. The Company owns, acquires, and develops cell therapy technologies for cancer and other diseases. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen chimeric antigen receptor (CAR) T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells are genetically engineered to recognize cancer cells to target and destroy them.
- Revenue in USD (TTM)0.00
- Net income in USD-16.31m
- Incorporated2022
- Employees5.00
- LocationCoeptis Therapeutics Holdings Inc105 Bradford Road, Suite 420WEXFORD 15090United StatesUSA
- Phone+1 (724) 934-6467
- Fax+1 (302) 636-5454
- Websitehttps://coeptistx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monopar Therapeutics Inc | 0.00 | -7.61m | 10.75m | 10.00 | -- | 1.44 | -- | -- | -0.5289 | -0.5289 | 0.00 | 0.4277 | 0.00 | -- | -- | 0.00 | -73.36 | -54.07 | -92.67 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Eterna Therapeutics Inc | 115.00k | -22.92m | 10.77m | 8.00 | -- | -- | -- | 93.62 | -4.25 | -4.25 | 0.0214 | -0.6307 | 0.0036 | -- | 0.2305 | 14,375.00 | -70.71 | -169.05 | -88.77 | -223.00 | -114.78 | -- | -19,912.17 | -682.61 | -- | -15.55 | 1.64 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| 22nd Century Group Inc | 29.75m | -62.89m | 11.03m | 64.00 | -- | -- | -- | 0.3708 | -40.02 | -97.93 | 17.94 | -3.23 | 0.40 | 5.90 | 5.47 | 464,796.90 | -66.29 | -46.78 | -92.49 | -54.18 | -33.09 | -2.11 | -165.75 | -107.95 | 0.4284 | -3.67 | 4.76 | -- | -20.49 | 4.03 | -76.94 | -- | 53.60 | -- |
| Avalo Therapeutics Inc | 1.45m | -142.88m | 11.16m | 19.00 | -- | -- | -- | 7.70 | -318.69 | -318.69 | 3.02 | -97.75 | 0.0181 | -- | 3.25 | 76,315.79 | -178.64 | -99.64 | -- | -154.42 | 54.90 | 84.69 | -9,853.73 | -613.58 | -- | -0.2415 | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Coeptis Therapeutics Holdings Inc | 0.00 | -16.31m | 11.19m | 5.00 | -- | 2.52 | -- | -- | -0.5804 | -0.5804 | 0.00 | 0.1197 | 0.00 | -- | -- | 0.00 | -212.70 | -36.90 | -378.58 | -37.81 | -- | -- | -- | -- | -- | -- | 0.349 | -- | -- | -- | 43.40 | -- | -- | -- |
| Oragenics Inc | 20.63k | -20.26m | 11.25m | 5.00 | -- | 10.89 | -- | 545.15 | -7.98 | -7.98 | 0.0079 | 0.5859 | 0.0026 | -- | -- | 4,126.00 | -258.71 | -97.60 | -312.34 | -106.24 | -- | -- | -98,214.93 | -36,169.75 | -- | -- | 0.0461 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Allarity Therapeutics Inc | 0.00 | -20.94m | 11.27m | 5.00 | -- | -- | -- | -- | -599.34 | -599.34 | 0.00 | -18.88 | 0.00 | -- | -- | 0.00 | -100.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.02 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -29.98m | 11.53m | 41.00 | -- | -- | -- | -- | -0.6765 | -0.6765 | 0.00 | -0.4079 | 0.00 | -- | -- | 0.00 | -382.78 | -- | -- | -- | -- | -- | -- | -- | -- | -27.45 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 11.54m | -- | -- | -- | 7.62 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 11.60m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| ABVC Biopharma Inc | 152.43k | -10.52m | 11.61m | 16.00 | -- | 1.01 | -- | 76.18 | -2.52 | -2.52 | 0.0352 | 1.06 | 0.0127 | -- | 0.3514 | 9,526.88 | -90.65 | -103.38 | -171.60 | -231.54 | -98.15 | 76.25 | -7,157.57 | -2,019.89 | -- | -3.28 | 0.153 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
| Guardion Health Sciences Inc | 12.06m | -5.12m | 11.69m | 9.00 | -- | 3.42 | -- | 0.9688 | -4.00 | -4.00 | 9.49 | 2.66 | 0.9718 | 2.63 | 5.96 | 1,340,280.00 | -41.26 | -77.90 | -47.92 | -86.55 | 43.43 | 42.45 | -42.46 | -176.93 | 6.49 | -4.24 | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
| Moleculin Biotech Inc | 0.00 | -26.82m | 11.74m | 18.00 | -- | 0.544 | -- | -- | -12.94 | -12.94 | 0.00 | 9.34 | 0.00 | -- | -- | 0.00 | -65.50 | -46.84 | -75.07 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
| GlucoTrack Inc | 0.00 | -8.74m | 11.83m | 6.00 | -- | 30.74 | -- | -- | -1.87 | -1.87 | 0.00 | 0.0703 | 0.00 | -- | -- | 0.00 | -520.58 | -94.01 | -2,110.63 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.3415 | -- | -- | -- | -60.02 | -- | -- | -- |
| Pioneer Green Farms Inc | 9.29k | -403.37k | 11.94m | 6.00 | -- | -- | -- | 1,285.15 | -0.0172 | -0.0172 | 0.0004 | -0.026 | 0.0154 | 0.3035 | -- | 1,548.33 | -66.94 | -- | -- | -- | 41.44 | -- | -4,341.98 | -- | 0.0106 | -30.89 | -- | -- | -- | -- | 35.41 | -- | -- | -- |
Data as of May 23 2024. Currency figures normalised to Coeptis Therapeutics Holdings Inc's reporting currency: US Dollar USD
12.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 3.03m | 8.40% |
| Creative Planning LLCas of 31 Mar 2024 | 645.10k | 1.79% |
| Meteora Capital LLCas of 31 Mar 2024 | 446.25k | 1.24% |
| Geode Capital Management LLCas of 31 Mar 2024 | 190.15k | 0.53% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 108.71k | 0.30% |
| Cambridge Investment Research Advisors, Inc.as of 31 Mar 2024 | 56.15k | 0.16% |
| Arista Wealth Management LLCas of 31 Mar 2024 | 47.33k | 0.13% |
| Mint Tower Capital BVas of 31 Mar 2024 | 45.00k | 0.13% |
| Sea Otter Advisors LLCas of 31 Mar 2024 | 45.00k | 0.13% |
| Ionic Capital Management LLCas of 31 Mar 2024 | 45.00k | 0.13% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
